tyrosine aminotransferase
Senast uppdaterad 18 aug 2020
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ask Patient
- Ljudversion
- Lägg till i föredragna källor på Google
Den TAT gene provides instructions for making a liver enzyme called tyrosine aminotransferase. This enzyme is the first in a series of five enzymes that work to break down the amino acid tyrosine, a protein building block found in many foods. Specifically, tyrosine aminotransferase converts tyrosine into a byproduct called 4-hydroxyphenylpyruvate. Continuing the process, 4-hydroxyphenylpyruvate is further broken down and ultimately smaller molecules are produced that are either excreted by the kidneys or used to produce energy or make other substances in the body.
Videoval för GenesVideobibliotek
Normal function
Den TAT gene provides instructions for making a liver enzyme called tyrosine aminotransferase. This enzyme is the first in a series of five enzymes that work to break down the amino acid tyrosine, a protein building block found in many foods. Specifically, tyrosine aminotransferase converts tyrosine into a byproduct called 4-hydroxyphenylpyruvate. Continuing the process, 4-hydroxyphenylpyruvate is further broken down and ultimately smaller molecules are produced that are either excreted by the kidneys or used to produce energy or make other substances in the body.
Conditions referring to this gene or chromosome
Other names
ATTY_HUMAN
L-tyrosine:2-oxoglutarate aminotransferase
tyrosine transaminase
Related patient information and medicines

Patient information leaflet
Mastocytos och mastcellssjukdomar
If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on the immune system (such as interferon), bone marrow transplant or... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new.

Patient information leaflet
Kronisk myeloisk leukemi
Treatment for the initial chronic phase The aim of treatment is to control the disease process, to ease any symptoms and to prevent (or delay) the progress... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Patient information leaflet
Muncancer
Dia... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that b person should receive a diagnosis or ruling out of cancer within 28 days av being referred urgently by their GP for suspected cancer. To confirm the diagnosis It is likely that you will need a biopsy. Cetuximab is an.

Medicine leaflet
Lapatinib tabletter
Lapatinib is given for the treatment of breast cancer. About lapatinib Type of medicine A tyrosine kinase inhibitor chemotherapy medicine Used for Treatment of breast cancer Also called Tyverb® Available as Tablets Lapatinib is a medicine which is given for the treatment of breast cancer Breast cancer which has progressed despite other treatment,.

Medicine leaflet
Nilotinib kapslar
It is important that you keep the regular appointments with your doct... About nilotinib Type of medicine A tyrosine kinase inhibitor chemotherapy medicine Used for Treatment of chronic myeloid leukaemia Also called Tasigna® Available as Capsules Nilotinib is a medicine which is given to treat leukaemia Leukaemia. Leukaemia is cancer of cells in.

Medicine leaflet
Erlotinib-tabletter
Erlotinib is given for the treatment of lung cancer, or for the treatment of cancer of the pancreas. Contact your doctor straightaway if you de... About erlotinib Type of medicine A tyrosine kinase inhibitor chemotherapy medicine Used for Lung cancer, and cancer of the pancreas Also called Tarceva® Available as Tablets Erlotinib is a medicine.
Vidare läsning och referenser
- tyrosine aminotransferase; MedlinePlus, National Library of Medicine.
- Bouyacoub Y, Zribi H, Azzouz H, Nasrallah F, Abdelaziz RB, Kacem M, Rekaya B, Messaoud O, Romdhane L, Charfeddine C, Bouziri M, Bouziri S, Tebib N, Mokni M, Kaabachi N, Boubaker S, Abdelhak S. Novel and recurrent mutations in the TAT gene in Tunisian families affected with Richner-Hanhart syndrome. Gene. 2013 Oct 15;529(1):45-9. doi: 10.1016/j.gene.2013.07.066. Epub 2013 Aug 13.
- Mehere P, Han Q, Lemkul JA, Vavricka CJ, Robinson H, Bevan DR, Li J. Tyrosine aminotransferase: biochemical and structural properties and molecular dynamics simulations. Protein Cell. 2010 Nov;1(11):1023-32. doi: 10.1007/s13238-010-0128-5. Epub 2010 Dec 10.
- Sivaraman S, Kirsch JF. The narrow substrate specificity of human tyrosine aminotransferase--the enzyme deficient in tyrosinemia type II. FEBS J. 2006 May;273(9):1920-9. doi: 10.1111/j.1742-4658.2006.05202.x.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
18 aug 2020 | Senaste versionen
1 Jan 2008 | Ursprungligen publicerad
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.

